Daraxonrasib's Frontline Signal Has to Prove the Chemo Still Belongs
Updated Phase 1/2 data show 60.7% responses in first-line metastatic pancreatic cancer. A single-arm cohort of 61 patients still leaves the chemotherapy question open.
Metastatic pancreatic cancer has a long history of producing small, fragile gains, which is why the numbers from Barcelona on Nov 20 read like a different disease. In an update from the RMC-GI-102 trial, the RAS inhibitor daraxonrasib added to gemcitabine and nab-paclitaxel produced a confirmed response rate of 60.7% in 61 previously untreated patients, with tumors disappearing from scans in five. Median progression-free survival came in at 12.8 months, and 76.6% of patients were alive at twelve months. The data were presented at the EORTC-NCI-AACR Symposium.
The benchmark being beaten
Most patients survive 8 to 11 months on standard chemotherapy, shrinkage appears in only 23% to 42% of them, and tumors typically resume growing after five to six months, according to the trial's lead investigator, Dr Wungki Park of Memorial Sloan Kettering. Against that range, a 60.7% response rate and a 12.8-month median PFS sit outside anything chemotherapy has produced in this disease, and Park described the PFS as nearly doubling the historical benchmark. He also flagged the caveat himself: these patients were not compared with patients receiving chemotherapy alone.
What the pill actually does
Daraxonrasib is an oral inhibitor that blocks RAS proteins in their active state, hitting mutant and wild-type forms rather than a single mutation. It works as a molecular glue, recruiting cyclophilin A to shut the switch off. That breadth matters because more than 90% of pancreatic tumors carry a RAS mutation.
Why single-arm numbers shrink
The cohort is 61 patients, all with RAS-mutant tumors, followed for a median of 18.3 months. That is a genotype-selected population in a single-arm design, precisely the setting where oncology effect sizes tend to compress once randomization assigns patients to a control arm. A 60.7% response rate reported without a comparator has historically been worth less than the same figure reported against one.
The reason this signal carries weight
The counterweight is the drug's own record under randomization, which its second-line results survived. In RASolute 302, a 500-patient randomized trial after one prior line, median overall survival was 13.2 months versus 6.7 months, median PFS was 7.2 months versus 3.6 months, and the response rate was 30% versus 11%. The approval followed on Aug 26, 2026, roughly 6.5 months ahead of the FDA's goal date. A sponsor whose single-arm data held up in a randomized head-to-head earns more benefit of the doubt on its next single-arm read. The first-line figure is not a clean analog, but it is far from a naive extrapolation.
The question RASolute 303 must answer
Whether daraxonrasib works is now the less interesting question. Whether the chemotherapy adds anything is the one RASolute 303 was built to answer. The randomized second-line PFS of 7.2 months came from the pill alone, in patients who had progressed on chemotherapy. The 12.8-month first-line PFS came from the pill plus two cytotoxic drugs, in patients who had received nothing. Those groups differ in prior treatment, so the comparison cannot separate the drug's contribution from the chemotherapy's, or say whether the doublet is worth its extra burden. Phase 3 RASolute 303, testing the drug alone and with chemotherapy against chemotherapy alone, includes a monotherapy arm that will. If daraxonrasib by itself approaches the combination's numbers, the added myelosuppression and infusion visits buy little. The FDA granted breakthrough designation to the combination on Sept 14, 2026, so both paths remain open.
A dose question hiding in the protocol
The approved monotherapy dose is 300 mg once daily. The first-line combination cohort used 200 mg. Why the lower dose was used alongside the doublet is a design question the Phase 3 program will settle. The combination itself remains investigational. The drug is already approved second line in the US and, since Nov 16, in Europe, and its labeled monotherapy toxicity is documented: dermatologic events in 86% of patients, stomatitis in 57%, diarrhea in 63%. In the combination cohort, grade 3 or higher treatment-related anemia reached 33% at the 40-patient interim look in April.
Why frontline matters so much here
Roughly 80% of pancreatic cancer patients are diagnosed after the disease has spread, which makes the frontline setting the place where most treatment decisions are made. About 55,000 people are diagnosed with pancreatic ductal adenocarcinoma in the US each year. A drug that works only after chemotherapy has failed touches a minority of that journey; one that works at diagnosis touches nearly all of it. The 61-patient cohort is a reason to run the trial, not a reason to skip it.